Treatment for Livedoid Vasculopathy

医学 梅德林 英语 皮肤病科 外科 内科学 儿科 政治学 法学 哲学 语言学
作者
Robert Micieli,Afsáneh Alavi
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:154 (2): 193-193 被引量:88
标识
DOI:10.1001/jamadermatol.2017.4374
摘要

Importance

Livedoid vasculopathy is a painful, ulcerative condition of the lower extremities for which no established treatment exists. Current treatment paradigms rely on low levels of evidence, primarily case reports and case series.

Objective

To systematically review the treatment for livedoid vasculopathy and synthesize the available clinical data.

Evidence Review

A systematic review of the literature using Ovid MEDLINE (covering the period January 1, 1946, through June 9, 2017) and Ovid EMBASE (covering January 1, 1947, through June 9, 2017) databases was performed with a broad and inclusive search strategy along with a subsequent search of the references of retrieved articles. All case series reports published in the English language and in a peer-reviewed journal discussing the treatment for livedoid vasculopathy diagnosis were included.

Findings

A total of 29 case series reports published in the English language and in a peer-reviewed journal discussed the treatment for livedoid vasculopathy. These reports represented a total of 339 patients, of whom 230 (68%) were female and 69 (20%) were male; sex was not stated for 40 patients. Treatment with anticoagulants, antiplatelets, anabolic steroids, thrombolytics, hyperbaric oxygen, intravenous immunoglobulins, vitamin supplementation, UV light, and a combination of 1 or more of these among other therapies had a favorable outcome. Anticoagulants were the most commonly used monotherapy, achieving a favorable response in 62 of 63 patients (98%). Anabolic steroids, intravenous immunoglobulins, and antiplatelets were the second, third, and fourth most commonly used treatments, respectively. All of these therapies were associated with good clinical outcomes. Adverse events were observed in 44 patients (13%).

Conclusions and Relevance

A variety of treatments with varying degrees of success have been used to treat livedoid vasculopathy. Randomized clinical trials should be performed in the future to better establish these treatments in clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
胡一菲发布了新的文献求助10
刚刚
科研栾完成签到,获得积分10
刚刚
共享精神应助Li采纳,获得10
刚刚
斯文败类应助霸气乐菱采纳,获得10
1秒前
zy发布了新的文献求助10
2秒前
景景发布了新的文献求助10
2秒前
3秒前
爆米花应助aimeejjr采纳,获得10
4秒前
小二郎应助Gin采纳,获得10
4秒前
珊珊发布了新的文献求助10
5秒前
SciGPT应助吴wu采纳,获得10
6秒前
喃恬完成签到,获得积分10
7秒前
小柒发布了新的文献求助30
7秒前
陈chen发布了新的文献求助10
7秒前
赘婿应助胡一菲采纳,获得10
8秒前
英俊的铭应助单薄初蓝采纳,获得10
8秒前
张康完成签到 ,获得积分10
8秒前
哈神爱xuex发布了新的文献求助100
8秒前
Orange应助杨天天采纳,获得10
9秒前
hjz发布了新的文献求助10
9秒前
星辰大海应助麋鹿采纳,获得10
9秒前
卷aaaa完成签到,获得积分10
9秒前
10秒前
lt0217发布了新的文献求助10
10秒前
iNk应助甜青提采纳,获得20
11秒前
科目三应助fddd采纳,获得10
11秒前
liu完成签到 ,获得积分10
11秒前
量子星尘发布了新的文献求助10
11秒前
魔幻香露完成签到,获得积分10
12秒前
核桃应助qingzhiwu采纳,获得10
13秒前
小黄发布了新的文献求助10
14秒前
14秒前
14秒前
14秒前
哈神爱xuex完成签到,获得积分10
14秒前
15秒前
16秒前
16秒前
16秒前
DDDDD发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
SOFT MATTER SERIES Volume 22 Soft Matter in Foods 1000
Zur lokalen Geoidbestimmung aus terrestrischen Messungen vertikaler Schweregradienten 1000
Storie e culture della televisione 500
Selected research on camelid physiology and nutrition 500
《2023南京市住宿行业发展报告》 500
Architectural Corrosion and Critical Infrastructure 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4885855
求助须知:如何正确求助?哪些是违规求助? 4170775
关于积分的说明 12942531
捐赠科研通 3931395
什么是DOI,文献DOI怎么找? 2157039
邀请新用户注册赠送积分活动 1175458
关于科研通互助平台的介绍 1080012